🚀 VC round data is live in beta, check it out!
PharmaEssentia Valuation Multiples
Discover revenue and EBITDA valuation multiples for PharmaEssentia and similar public comparables like Alkem Laboratories, ABL Bio, Kelun, Merus and more.
PharmaEssentia Overview
About PharmaEssentia
PharmaEssentia Corp is engaged in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug pattern developments. It focuses on Hematology, Oncology, and Infectious Diseases. The company derives its revenue from the sales of medicine products. Geographically, the company generates maximum revenue from America, followed by Europe, Asia (excluding Taiwan), and Taiwan.
Founded
2000
HQ
Employees
350
Website
Sectors
Financials (LTM)
EV
$7B
PharmaEssentia Financials
PharmaEssentia reported last 12-month revenue of $569M and EBITDA of $213M.
In the same LTM period, PharmaEssentia generated $509M in gross profit, $213M in EBITDA, and $190M in net income.
Revenue (LTM)
PharmaEssentia P&L
In the most recent fiscal year, PharmaEssentia reported revenue of $497M and EBITDA of $171M.
PharmaEssentia expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $569M | XXX | $497M | XXX | XXX | XXX |
| Gross Profit | $509M | XXX | $437M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $213M | XXX | $171M | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 34% | XXX | XXX | XXX |
| EBIT Margin | 34% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $190M | XXX | $160M | XXX | XXX | XXX |
| Net Margin | 33% | XXX | 32% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PharmaEssentia Stock Performance
PharmaEssentia has current market cap of $7B, and enterprise value of $7B.
Market Cap Evolution
PharmaEssentia's stock price is $21.59.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $7B | 0.2% | XXX | XXX | XXX | $0.48 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPharmaEssentia Valuation Multiples
PharmaEssentia trades at 11.5x EV/Revenue multiple, and 30.8x EV/EBITDA.
EV / Revenue (LTM)
PharmaEssentia Financial Valuation Multiples
As of April 8, 2026, PharmaEssentia has market cap of $7B and EV of $7B.
Equity research analysts estimate PharmaEssentia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PharmaEssentia has a P/E ratio of 38.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV/Revenue | 11.5x | XXX | 13.2x | XXX | XXX | XXX |
| EV/EBITDA | 30.8x | XXX | 38.5x | XXX | XXX | XXX |
| EV/EBIT | 33.5x | XXX | 41.9x | XXX | XXX | XXX |
| EV/Gross Profit | 12.9x | XXX | 15.0x | XXX | XXX | XXX |
| P/E | 38.0x | XXX | 45.0x | XXX | XXX | XXX |
| EV/FCF | 64.8x | XXX | 62.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PharmaEssentia Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PharmaEssentia Margins & Growth Rates
PharmaEssentia's revenue in the last 12 month grew by 58%.
PharmaEssentia's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $0.8M for the same period.
PharmaEssentia's rule of 40 is 99% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PharmaEssentia's rule of X is 184% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
PharmaEssentia Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 58% | XXX | 54% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 84% | XXX | 92% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 99% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 184% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PharmaEssentia Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alkem Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| ABL Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Kelun | XXX | XXX | XXX | XXX | XXX | XXX |
| Merus | XXX | XXX | XXX | XXX | XXX | XXX |
| Wantai BioPharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PharmaEssentia M&A Activity
PharmaEssentia acquired XXX companies to date.
Last acquisition by PharmaEssentia was on XXXXXXXX, XXXXX. PharmaEssentia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PharmaEssentia
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPharmaEssentia Investment Activity
PharmaEssentia invested in XXX companies to date.
PharmaEssentia made its latest investment on XXXXXXXX, XXXXX. PharmaEssentia invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PharmaEssentia
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PharmaEssentia
| When was PharmaEssentia founded? | PharmaEssentia was founded in 2000. |
| Where is PharmaEssentia headquartered? | PharmaEssentia is headquartered in Taiwan. |
| How many employees does PharmaEssentia have? | As of today, PharmaEssentia has over 350 employees. |
| Who is the CEO of PharmaEssentia? | PharmaEssentia's CEO is Ko-Chung Lin. |
| Is PharmaEssentia publicly listed? | Yes, PharmaEssentia is a public company listed on Taiwan Stock Exchange. |
| What is the stock symbol of PharmaEssentia? | PharmaEssentia trades under 6446 ticker. |
| When did PharmaEssentia go public? | PharmaEssentia went public in 2014. |
| Who are competitors of PharmaEssentia? | PharmaEssentia main competitors are Alkem Laboratories, ABL Bio, Kelun, Merus. |
| What is the current market cap of PharmaEssentia? | PharmaEssentia's current market cap is $7B. |
| What is the current revenue of PharmaEssentia? | PharmaEssentia's last 12 months revenue is $569M. |
| What is the current revenue growth of PharmaEssentia? | PharmaEssentia revenue growth (NTM/LTM) is 58%. |
| What is the current EV/Revenue multiple of PharmaEssentia? | Current revenue multiple of PharmaEssentia is 11.5x. |
| Is PharmaEssentia profitable? | Yes, PharmaEssentia is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PharmaEssentia? | PharmaEssentia's last 12 months EBITDA is $213M. |
| What is PharmaEssentia's EBITDA margin? | PharmaEssentia's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of PharmaEssentia? | Current EBITDA multiple of PharmaEssentia is 30.8x. |
| What is the current FCF of PharmaEssentia? | PharmaEssentia's last 12 months FCF is $101M. |
| What is PharmaEssentia's FCF margin? | PharmaEssentia's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of PharmaEssentia? | Current FCF multiple of PharmaEssentia is 64.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.